Foghorn therapeutics to participate at the 2022 guggenheim targeted protein degradation day

Cambridge, mass., march 11, 2022 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that foghorn will participate at the 2022 guggenheim targeted protein degradation day which is being held virtually on march 16th, 2022. with an initial focus in oncology, foghorn's gene traffic control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
FHTX Ratings Summary
FHTX Quant Ranking